Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,569.78 -24.85 (-0.54%) Dow
36,204.44 -41.06 (-0.11%) Nasdaq
14,185.49 -119.54 (-0.84%) Bitcoin USD
41,890.79 +1,823.56 (+4.55%) CMC Crypto 200
860.54 +1.83 (+0.21%)
LLY Jan 2024 150.000 call
| Previous close | 441.00 |
| Open | 441.00 |
| Bid | 432.00 |
| Ask | 440.90 |
| Strike | 150.00 |
| Expiry date | 2024-01-19 |
| Day's range | 441.00 - 441.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
ZacksLilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
ZacksAltimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Motley Fool1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Dividend stocks have a well-earned reputation for outperformance. Modern portfolio theory (MPT), however, indicates that growth investors should strictly adhere to a couple of critical guidelines when picking dividend stocks for their portfolios. Among the most important guideposts recommended by the peer-reviewed MPT literature are selecting stocks with dividends lower than the average of the benchmark S&P 500 index; selecting stocks with premium valuations and a track record of positive annual returns; and selecting stocks in fast-growing sectors like healthcare or technology.
